Archives of Iranian Medicine · 2021 · 28 citations · 8 references
PharmacyInfectious DiseasesPharmacotherapyCritical Care PharmacotherapyImmunotherapyInfectious Disease PharmacotherapyAcute Respiratory Distress SyndromeAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyIntensive Care MedicineInterferon-based TherapyClinical SymptomsCombination TherapyCovid-19-associated Acute Respiratory Distress SyndromeCytokine Storm SyndromeIndividualized Treatment RegimensRibavirin TherapySevere Acute Respiratory SyndromeTreatment Of Coronavirus Infections
Background: Severe coronavirus disease 2019 (COVID-19) may lead to the cytokine storm syndrome which may cause acute respiratory failure syndrome and death. Our aim was to investigate the therapeutic effects of infliximab, intravenous gammaglobulin (IVIg) or combination therapy in patients with severe COVID-19 disease admitted to the intensive care unit (ICU). Methods: In this observational research, we studied 104 intubated adult patients with severe COVID-19 infection (based on clinical symptoms, and radiographic or CT scan parameters) who were admitted to the ICU of a multispecialty hospital during March 2020 in Tehran, Iran. All cases received standard treatment regimens as local protocol (Oseltamivir + hydroxychloroquine + lopinavir/ritonavir or sofosbuvir or atazanavir ± ribavirin). The cases were grouped as controls (n = 43), infliximab (n = 27), IVIg (n = 23) and combination (n = 11). Results: There was no significant difference between controls and treatment groups in terms of underlying diseases or the number of underlying diseases. The mean age (SD) of cases was 72.42 (16.06) in the control group, 64.52 (12.965) in IVIg, 63.40 (17.57) in infliximab and 64.00 (11.679) in combination therapy; ( P = 0.047, 0.031 and 0.11, respectively). Also, 37% in the infliximab group, 26.1% in IVIg, 45.5% in combination therapy, and 62.8% in the control group expired (all P < 0.05). Hazard ratios were 0.31 in IVIg (95% CI: 0.12-0.76, P = 0.01), 0.30 in infliximab (95% CI: 0.13-0.67, P = 0.004), 0.39 in combination therapy (95% CI: 0.12-1.09, P = 0.071). Conclusion: According to the findings of this study, it seems that infliximab and IVIg, alone or together, in patients with severe COVID-19 disease can be considered an effective treatment.
8
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta, Daniel F. McAuley, Michael Brown et al. · The Lancet · 2020 · 10.2K citations · Full text
Yinghui Jin, Lin Cai, Zhenshun Cheng et al. · Military Medical Research · 2020 · 2.4K citations · Full text
Veterinary Medicine, Infectious Disease Control, Infectious Diseases +17
Bita Shakoory, Joseph A. Carcillo, W. Winn Chatham et al. · Critical Care Medicine · 2015 · 854 citations · Full text